Molecular Research Targeting Plasma-Cell Myeloma

Dear Colleagues,

Multiple myeloma (MM) is a systemic disorder of plasma cells characterized by chromosomal instability as well as significant pathophysiological and clinical heterogeneity. According to recent epidemiologic data, MM is the second most common hematologic malignancy. Treatment of MM with combinations of novel regimens based on immunomodulatory agents, proteasome inhibitors, glucocorticoids, and immunotherapies, including monoclonal/bispecific antibodies and genetically modified immune cells, has resulted in improved outcomes over recent years. However, most patients experience relapses and develop drug-resistant diseases, since further studies involving basic research identifying potentially targetable molecular pathways, epigenetic alterations, and modulation of the immune system are still needed to lay the foundation for future, more effective anti-myeloma therapies.

Therefore, I cordially invite you to share your expertise in MM molecular research and contribute original articles reporting results of both preclinical and human studies as well as reviews focused on immune system modulation, potentially targetable molecular pathways, epigenetic alterations, and drug resistance mechanisms in multiple myeloma.

Prof. Dr. Bogusław Machaliński
Prof. Dr. Marek Hus
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• abnormal plasma cell
• multiple myeloma
• immunotherapy
• epigenetic
• drug resistance